AssetMark Inc’s Ironwood Pharmaceuticals IRWD Stock Holding History

AssetMark Inc’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-17	Closed	-$194	–	2019
2023 Q4	$194	Buy	+17	New	+$168	﹤0.01%	1774

Other funds holding IRWD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

AssetMark Inc's IRWD Position: Q1 2024 in Review

AssetMark Inc sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2024, closing a stake of 17 shares — an estimated $194 sold.

AssetMark Inc first reported a position in IRWD in Q4 2023 and held it in 1 quarter. The position peaked at $194 in Q4 2023. 261 funds tracked by Wall St. Rank hold IRWD as of Q1 2024.

AssetMark Inc reported no remaining Ironwood Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
AssetMark Inc sold 17 Ironwood Pharmaceuticals shares in Q1 2024, an estimated $194.
AssetMark Inc first reported a position in Ironwood Pharmaceuticals in Q4 2023 and held it in 1 quarter.
AssetMark Inc's Ironwood Pharmaceuticals position peaked at $194 in Q4 2023.
261 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2024.

Based on AssetMark Inc's 13F filing for Q1 2024, filed 7 May 2024.